

Citius, Altius, Fortius: Performance in a Bottle for CAR T-Cells

Asma Ayari¹, Roddy S. O'Connor^{2,3*}

¹Nucleus Biologics, LLC, San Diego, CA, USA

²Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

³Department of Pathology and Laboratory Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA

*Correspondence should be addressed to Roddy S. O'Connor; occonnorr@penmedicine.upenn.edu

Received date: November 02, 2020, **Accepted date:** November 25, 2020

Copyright: © 2020 Ayari A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The renewed interest in understanding how activated T cells alter their metabolism to support their growth and differentiation has led to several innovative advances in synthetic biology; culminating in a number of genetic and pharmacologic approaches aimed at improving the anti-tumor function of adoptively transferred T cells. Indeed, the growing field of immunometabolism has accelerated rapidly giving rise to exciting discoveries and exploratory studies revealing how T cells balance metabolic adaptations in response to intrinsic and extrinsic regulatory cues. Central to this body of work, we showed how chimeric antigen receptors (CAR)-induced metabolic reprogramming is an important determinant of efficacy and clinical outcome in blood-based malignancies [1]. CAR T-cell production involves a rigorous, and systematic *ex-vivo* expansion regime involving activation; genetic modification with either a CAR or tumor-specific T cell receptor (TCR); and proliferative phase which often lasts 14 days. As CAR T-cells progressively differentiate over time in culture, a process that impairs engraftment and potency following adoptive transfer, it's surprising that the metabolic composition of clinical grade cell culture mediums has been largely understudied. Increasing evidence suggests that subtle adjustments in medium formulation can have a dramatic impact on T cell bioactivity and anti-tumor function in several preclinical models of cancer. In a recent article, we provide direct evidence that standard medium formulations are suboptimal, and introduce a serum-free, concentrated, platelet extract as a superior alternative to human serum in clinical-grade medium for CAR T-cells [2].

What prompted our study? With the increased number of CAR-T cell clinical trials worldwide, a critical inflection point will be reached where the demand for human serum exceeds its supply. A disruption in the supply chain, and a decline in human serum availability will provide an insurmountable barrier to CAR T-cell immunotherapies against cancer. In the course of our studies, we identified a serum-free, concentrated, platelet extract, "Phx", that optimized gene transfer into primary human T cells, increases effector function *in vitro*, and improves the anti-tumor potency of CAR-T cells *in vivo*. Future efforts will uncover if Phx can substitute for HS in freezing medias. A model describing our findings is presented in Figure 1.

Using an LC-MS-based screen, we show that carnosine is enriched in Phx relative to human serum. Carnosine (beta-alanyl-L-histidine) is a dipeptide molecule, highly concentrated in skeletal muscle and brain. Carnosine has been shown to buffer proton accumulation, neutralize free radicals, and chelate metal ions [3]. We provide novel evidence that carnosine enhances the metabolic fitness of activated T cells. It's well established that activated T cells undergo a metabolic shift to glycolysis support their increased energetic and biosynthetic demands. Committing to glycolysis centers on a paradoxical axis: metabolizing glucose to lactic acid supports high rates of ATP replenishment but creates an acidic milieu that impairs overall functional competence. Carnosine has an intrinsic ability to neutralize the increase in extracellular acidification, skewing metabolism towards an oxidative phenotype. Competition for oxygen is an important




Figure 1: *In vitro* improvement of T cell proliferation and transduction efficiency in serum-free media supplemented with Phx (platelet lysate).

determinant of efficacy in adoptive immunotherapies. Delgoffe and coworkers showed how CD8⁺ TiL cells were particularly vulnerable to oxygen depletion in xenograft models of melanoma [4]. Compared to T cells that evacuated solid tumors and migrated to nearby lymph nodes, the ability of CD8⁺ TiLs to consume oxygen is suppressed and mitochondrial function is impaired. Restoring their oxidative state enhances the efficacy of anti-PD-1 immune checkpoint blockade [5] Our findings suggest that carnosine confers a superior oxidative state to cultured T cells; an effect that often underlies improved mitochondrial function. Our study implicates a novel role for carnosine in medium formulations designed for adoptive immunotherapies. Phx also contains higher levels of monosaccharide derivatives including glucosamine-6-phosphate, D-sedoheptulose-1/7 biphosphate, and glucose-1 phosphate, as well as phospholipid and

nucleotide derivatives compared to human serum. How their abundance impacts T cells during the *ex-vivo* expansion phase is unknown.

Bypassing the local restrictions of an acidic milieu using carnosine gives rise to T cells with superior metabolic fitness. Circulating T cells are exposed to Carnosinase-1 (CN1) which is abundant in serum and cleaves the dipeptide by hydrolysis. In its free form, L-histidine has weak buffering capacity at physiologic ranges. For this reason, supplying carnosine in its free form, or in Phx, to T cells during *ex-vivo* culture is an ideal strategy to improve their performance following adoptive transfer. As tumor cells establish acidic environments to suppress T cell cytolytic activity [6], the findings from our work suggest that Carnosine “loaded” T cells may have a performance edge in these environments.

There are inherent challenges in delivering CAR transgenes to healthy volunteer as well as patient T cells. Polybrene and Chloroquine which bridge the virus to the T cell membrane, and restrict virus degradation in the lysosome, respectively, are commonly used to enhance retroviral-mediated gene delivery in stem cells. These are not widely used in T cell therapies. Here, Phx significantly enhanced lentiviral-mediated gene expression. These findings have important implications for reducing lentiviral production costs in CAR –T manufacturing process. Interestingly, carnosine was an important factor in Phx supporting lentiviral gene transfer into activated T cells. Lentiviral infection efficiencies increased from 31% to 43% when standard medium was supplemented with 30 mM carnosine. Future studies will determine the potential benefit of raising carnosine levels further in Phx-conditioned medium.

The components of medium used to fuel the expansion and differentiation of T cells for adoptive immunotherapies should be critically evaluated. Subtle changes in media formulation such as changing protein source from human serum to Phx has a dramatic impact on the effectiveness of T cell therapies. Using a human xenograft model of neuroblastoma, the anti-tumor function of GD-2-specific CAR T-cells was significantly enhanced in Phx relative to HS. Examining circulating lymphocyte numbers revealed that the overall persistence of adoptively transferred T cells was also significantly higher in Phx vs HS. These findings add to the growing body of work showing how metabolic reprogramming events during the *ex-vivo* expansion phase have immediate translational relevance for the clinical sector. OT- 1 T cells expanded in medium conditioned with L-arginine had increased anti-tumor function in a B16 murine model of melanoma [7]. Loss-of-function approaches show that pharmacologic inhibition of glycolysis enhances the differentiation state, persistence, and anti-tumor function, of adoptively transferred T cells [8,9]. Limiting activity of the glycolytic enzyme LDHA during T cell expansion led to increased efficacy in murine models of cancer [10]. Pharmacologic inhibiting P38 MAPK improved the efficacy of mouse anti-tumor T cells [11]. Implicit in these findings is that glycolysis supports effector function, and limiting effector differentiation prior to adoptive transfer yields progeny with superior engraftment following infusion. Complementing these results further, a recent paper showed how transient glucose restriction led to superior anti-tumor function following adoptive T cell transfer [12].

Adoptive cell therapies rely on the ability of activated T cells to undergo robust proliferation and differentiate into effector cell with cytolytic activity against cancer. Heterogeneity within the differentiating population ensure that a subset of T cells develop into memory cells, a stem-like lineage necessary for long-lasting immunity. Memory

T cells are metabolically distinct from effector cells and can be distinguished by an increased mitochondrial content [1,13], and energy generating capacity [1,14]; while the study itself doesn't identify a clear impact of Phx on the composition of naïve-like, central memory, or effector memory subsets (at least using standard flow cytometry panels), further analyses with RNA-Seq may reveal unique differentiation patterns underlying the superior performance of these CAR T-cells.

Optimizing media for cellular therapies has appeal across a broad clinical sector. Reconfiguring medium formulations to enhance T cell persistence, cytolytic function, and tumor clearance is an important priority in the CAR T-cell domain. As seen in this article, changing protein source from human serum to Phx, had a profound impact on cytolytic function *in vitro* and anti-tumor potency *in vivo*. By challenging the existing paradigm, and questioning the necessity of serum in current medium formulations, the article highlights an underappreciated role of medium formulation for enhancing cell therapies against cancer.

Funding

The authors acknowledge funding from grant R01 CA226983-03.

References

1. Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey Jr AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. *Immunity*. 2016 Feb 16;44(2):380-90.
2. Ghassemi S, Martinez-Becerra FJ, Master AM, Richman SA, Heo D, Leferovich J, et al. Enhancing Chimeric Antigen Receptor T Cell Anti-Tumor Function through Advanced Media Design. *Molecular Therapy-Methods & Clinical Development*. 2020 Sep 11;18: 595-606.
3. Brosnan ME, Brosnan JT. Histidine Metabolism and Function. *The Journal of Nutrition*. 2020 Oct;150(Supplement_1):2570S-5S.
4. Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. *Immunity*. 2016 Aug 16;45(2):374-88.
5. Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. *Cancer Immunology Research*. 2017 Jan 1;5(1):9-16.

6. García-Cañaveras JC, Chen L, Rabinowitz JD. The tumor metabolic microenvironment: lessons from lactate. *Cancer Research*. 2019 Jul 1;79(13):3155-62.
7. Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. *Cell*. 2016 Oct 20;167(3):829-42 e813.
8. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nature Medicine*. 2018 May;24(5):563-71.
9. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. *The Journal of Clinical Investigation*. 2013 Oct 1;123(10):4479-88.
10. Hermans D, Gautam S, García-Cañaveras JC, Gromer D, Mitra S, Spolski R, et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity. *Proceedings of the National Academy of Sciences*. 2020 Mar 17;117(11):6047-55.
11. Gurusamy D, Henning AN, Yamamoto TN, Yu Z, Zacharakis N, Krishna S, et al. Multi-phenotype CRISPR-Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies. *Cancer Cell*. 2020 Jun 8;37(6):818-33 e819.
12. Geltink RI, Edwards-Hicks J, Apostolova P, O'Sullivan D, Sanin DE, Patterson AE, et al. Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy. *Nature Metabolism*. 2020 Aug;2(8):703-16.
13. van der Windt GJ, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. *Immunological Reviews*. 2012 Sep;249(1):27-42.
14. van der Windt GJ, O'Sullivan D, Everts B, Huang SC, Buck MD, Curtis JD, et al. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. *Proceedings of the National Academy of Sciences*. 2013 Aug 27;110(35):14336-41.